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Can we treat post cardiac arrest shock by removing cytokines from circulation 
with high cut-off veno-venous hemodialysis? 
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Circulatory failure with clinical features resembling septic shock, is a common 
complication in patients resuscitated after an out-of-hospital cardiac arrest (OHCA) 1. 
A well-known feature in these critically ill patients, is an inflammatory response the 
magnitude of which is associated with organ failure, which appears to contribute to 
their long-term outcome 2. Plasma levels of inflammatory biomarkers correlate with 
the severity of refractory shock and vasopressor requirements during post-
resuscitation care, and appear associated with poor neurological outcomes 3-5.   
 A variety of treatment modalities have been tried in an attempt to modify the 
inflammatory response in the past. Targeted temperature management (TTM) is one 
such therapeutic intervention that is commonly applied in post cardiac arrest patients. 
However, despite of the proven effects of this treatment modality, the post-hoc 
analysis of the TTM trial, that compared a target temperature of 33°C versus 36°C 
showed no statistical difference in the inflammatory response between these two 
temperature goals 6,7.  
 Another interesting treatment option is the use of corticosteroids. In patients with 
sepsis, the use of corticosteroids may not improve outcome, but does appear to 
shorten the time patients require vasopressor therapy 8. This is in contrast to patients 
with traumatic brain injury, where the use of corticosteroids worsens neurologic 
outcome. 9. , In victims of cardiac arrest with return of spontaneous circulation, a 
small randomized, controlled pilot trial, showed that the use of corticosteroids 
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significantly reduced the levels of plasma IL-6, but failed to reduce the need for 
vasopressors 4.    
 In this issue of Resuscitation, Geri and colleagues present the results of the 
elegant HYPERDIA trial, a small proof-of-concept study, aiming at using high cut-
off veno-venous hemodialysis (HCO-CVVHD) in an attempt to remove pro-
inflammatory cytokines and thereby, alleviating the need for vasopressors10. In 
sepsis, this method has been demonstrated to lower plasma cytokine concentrations 
and reduce vasopressors need 11. In the HYPERDIA trial, 35 patients were 
randomized to receive two sessions of HCO-CVVH with CVVH in between if 
needed during the first 48 hours in the interventional group CVVH as deemed 
necessary by the treating clinician in the control group. Despite the intuitive appeal of 
this hypothesis, the study did not show any difference in time to  weaning  
vasopressors, or the levels over time of multiple important cytokines. 
 There are several possible explanations for these interesting findings. One thing that 
is difficult to control for, is the fact that any form of continuous renal replacement 
therapy in of by itself, may lower blood pressure and increase the need for 
vasopressors. Indeed, prolonged vasopressor need is not that common in OHCA 
patients. Moreover, the use of higher doses of vasopressors in order to improve blood 
pressure in OHCA patients, does not appear to be associated with harm 12. 
It is important to note that the plasma levels of proinflammatory cytokines recorded 
by the authors were much lower, compared to those reported in septic shock patients 
and as the investigators point out, the low concentration gradient may have decreased 
the efficacy of the method 11,13. Furthermore, renal replacement treatment such as 
hemodialysis (HD) is not an immunologically neutral treatment. It can induce 
inflammation due to activation of complement and other immune mechanisms on the 
surface of the tubing systems and membranes of the HD-apparatus 14. The possible 
beneficial impact of cytokine removal on the systemic inflammatory balance may be 
countered by the activation of other proinflammatory mechanisms.  
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What is more important is that even though the circulatory failure following cardiac 
arrest resembles septic shock, the underlying pathophysiology is largely different15. 
In sepsis, the cytokines are produced in response to invading microorganisms, whose 
antigens remain in the body for a long time, driving continuous systemic 
inflammation and adaptive immune response. In cardiac arrest, the cytokines reflect a 
non-specific inflammatory reaction to transient whole body ischaemia. It is possible 
that for an intervention like this to work, it would need to be started very early, and 
this is not possible in the clinical setting. Future research should explore in more 
detail the inflammatory mechanisms triggered in the tissues by whole body 
ischaemia, in order to identify potential targets for inhibiting the inflammatory 
response on the tissue level. A translational approach combining the expertise of 
researchers of basic immunology and clinical intensive care might prove worthy.  
We recognize that conducting randomized, controlled trials in  post resuscitation care 
patients is very difficult. Even more so with a very advanced and labor-intensive 
intervention such as CVVH. The HYPERDIA investigators are to be congratulated 
for conducting this very important proof-of-concept study.    
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